Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
14:37:15 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



Q:ACHFF - ARCH BIOPARTNERS INC - http://www.archbiopartners.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ACHFF - Qnot subscribed1.406-0.094-6.311.416161.48  1.48  1.4061.88  0.7215:32:45Apr 1615 min RT 2¢

Recent Trades - Last 10 of 16
Time ETExPriceChangeVolume
15:32:45Q1.406-0.0942,000
15:30:08Q1.41-0.09100
15:05:04Q1.41-0.09100
14:29:32Q1.415-0.085500
14:23:33Q1.42-0.083,500
14:02:29Q1.42-0.08700
13:32:57Q1.445-0.055600
13:12:15Q1.45-0.05300
13:12:15Q1.45-0.05300
13:12:15Q1.45-0.05600

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-16 07:14U:ACHFFNews ReleaseSt. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
2024-04-03 07:00U:ACHFFNews ReleaseUHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
2024-04-02 07:26U:ACHFFNews ReleaseArch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
2024-03-18 07:28U:ACHFFNews ReleaseArch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2
2024-03-15 07:05U:ACHFFNews ReleaseUniversity of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
2024-03-07 07:26U:ACHFFNews ReleaseArch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
2024-02-27 07:25U:ACHFFNews ReleaseArch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as a New Treatment to Prevent Acute Kidney Injury
2024-01-10 07:26U:ACHFFNews ReleaseArch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
2024-01-03 07:33U:ACHFFNews ReleaseArch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
2023-12-21 07:30U:ACHFFNews ReleaseArch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide
2023-12-18 08:25U:ACHFFNews ReleaseGrant of Options to Directors and Officers
2023-12-13 07:25U:ACHFFNews ReleaseArch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide
2023-10-24 07:30U:ACHFFNews ReleaseShares for Interest Debt Settlement
2023-09-22 07:00U:ACHFFNews ReleaseArch Biopartners Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide
2023-07-31 18:02U:ACHFFNews ReleaseArch Biopartners Engages Independent Trading Group as Market Maker
2023-06-27 07:15U:ACHFFNews ReleaseArch Biopartners Receives Permission From U.S. FDA to Proceed With Phase II Acute Kidney Injury Trial